Acura Pharmaceuticals extends debt maturity, secures additional loans from AD Pharma, warns of possible shutdown

ACURA PHARMACEUTICALS, INC

Received $300k in three new loans from Abuse Deterrent Pharma, raising principal to $9,294,279 at 5.25% interest.
Amended license agreement for LTX-03, extending FDA NDA acceptance deadline from Dec 31, 2025 to June 30, 2026.
Extended maturity of secured promissory note and warrant expiration to June 30, 2026.
AD Pharma now directly owns approximately 65% of Acura's outstanding common stock.
Company warns it may scale back operations or seek bankruptcy protection if additional financing is not obtained by end of December 2025.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 loans with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000 loans
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC maturing June 30, 2026.

Counterparty: Abuse Deterrent Pharma, LLC
Maturity: June 30, 2026
Event: amendment

Exact text from the filing

This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC (AD Pharma) valued at $100,000 loans (effective 2025-11-12).

Action: entry
Agreement: credit facility
Counterparty: Abuse Deterrent Pharma, LLC (AD Pharma)
Value: $100,000 loans
Effective: 2025-11-12

Exact text from the filing

On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ACURA PHARMACEUTICALS, INC amended Amended Agreement with AD Pharma (effective 2025-12-22).

Action: amendment
Agreement: license
Counterparty: AD Pharma
Effective: 2025-12-22

Exact text from the filing

This amendment #13 has an effective date of December 22, 2025 and extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 from December 31, 2025 to June 30, 2026 (“NDA Acceptance Date”) (“Amended Agreement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ACURA PHARMACEUTICALS, INC amended Warrant with AD Pharma (effective 2025-12-22).

Action: amendment
Counterparty: AD Pharma
Effective: 2025-12-22

Exact text from the filing

nd December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ACURA PHARMACEUTICALS, INC amended Amended Note with AD Pharma (effective 2025-12-22).

Action: amendment
Agreement: credit facility
Counterparty: AD Pharma
Effective: 2025-12-22

Exact text from the filing

This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.

View on SEC.gov

307 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-124500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.